Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

A variant of the virus caused disease in people in 1997, when there was a small but deadly outbreak in Hong Kong. Eighteen ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for ...

Biopharma innovator Alchemab Therapeutics, whose labs are in Cambridge UK, is collaborating with multinational pharma giant ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...

"This is going to be a broad approach. ... There's a big list to go after, but we're committed to make a difference," ...

SPRINGFIELD, Ill. – The Illinois Department of Public Health (IDPH) has approved four new conditions for treatment with ...

A Swiss national who was arrested and accused of spying in Iran died by suicide in prison on Thursday, according to Mizan ...